RhumbLine Advisers
SION

RhumbLine Advisers’s Sionna Therapeutics SION Stock Holding History

RhumbLine Advisers’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$734K Buy
18,308
+614
+3% +$23.4K ﹤0.01% 2368
2025
Q4 		$728K Buy
17,694
+454
+3% +$17.2K ﹤0.01% 2413
2025
Q3 		$507K Sell
17,240
-430
-2% -$9.36K ﹤0.01% 2691
2025
Q2 		$307K Buy
+17,670
New +$232K ﹤0.01% 2974

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RhumbLine Advisers's SION Position: Q1 2026 in Review

RhumbLine Advisers increased its Sionna Therapeutics (SION) stake by 3.5% in Q1 2026, buying an estimated $23.4K and bringing the position to 18,308 shares worth $734K. The position accounts for ﹤0.01% of the portfolio, ranked #2368.

RhumbLine Advisers first reported a position in SION in Q2 2025 and has held it in 4 quarters since. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

  • RhumbLine Advisers held 18,308 shares of Sionna Therapeutics worth $734K as of Q1 2026.
  • RhumbLine Advisers bought 614 Sionna Therapeutics shares in Q1 2026, an estimated $23.4K.
  • Sionna Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2368 holding.
  • RhumbLine Advisers first reported a position in Sionna Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.